

Receipt date: 03/22/2006

10521929 - GAU: 1614

FORM PTO-1449
(REV. 7-85)U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICE

ATTY. DOCKET NO.

DN/4-32586A

APPLICATION NO.

10/521,929

APPLICANT

OHTSURU ET AL.

FILING DATE

AUGUST 5, 2005

Group

Exr. Leslie A. Royds, AU 1614

INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)



U.S. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE
	AA					
	AB					
	AC					
	AD					
	AE					
	AF					
	AG					
	AH					
	AI					
	AJ					
	AK					
	AL					

FOREIGN PATENT DOCUMENTS

	DOCUMENT NUMBER	DATE	OFFICE	CLASS	SUBCLASS	TRANSLATION	
						YES	NO
AM	* WO 99/03854	01/28/99	WIPO			<input type="checkbox"/>	<input type="checkbox"/>
AN	* EP 0 564 409 [in German; English claims equivalent in AU-B-35694/93]	10/06/93	Europe			<input type="checkbox"/>	<input type="checkbox"/>
AO	* AU-B-35694/93 (English claims corresponding to EP 0 564 409)	10/07/93	Australia			<input type="checkbox"/>	<input type="checkbox"/>
AP						<input type="checkbox"/>	<input type="checkbox"/>
AQ						<input type="checkbox"/>	<input type="checkbox"/>

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent pages, Etc.)

AR	Cohen, Residence in General Surgery, Homepage of the Washington University School of Medicine, Dept. of Surgery (1997, 1998).
AS	* Cohen et al., "Inhibition of Medullary Thyroid Carcinoma Cell Proliferation and RET Phosphorylation by Tyrosine Kinase Inhibitors", <i>Surgery</i> , Vol. 132, No. 6, pp. 960-968 (2002).
AT	Eng, "Biology of Neoplasia. RET Proto-Oncogene in the Development of Human Cancer", <i>J Clin Oncol</i> , Vol. 17, No. 1, pp. 380-393 (1999).

EXAMINER /Leslie A. Royds/ (02/18/2009)

DATE CONSIDERED

*EXAMINER: Initial of reference considered, whether or not citation is in conformance with MPEP 609: Draw a line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /LAR/ (02/18/2009)

FORM PTO-1449
(REV. 7-85)U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICE

INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

ATTY. DOCKET NO.
DN/4-32586A
APPLICATION NO.
10521.929
APPLICANT
OHTSURU ET AL.
FILING DATE
AUGUST 5, 2005

Group

Exr. Leslie A. Royds, AU 1614

EXAMINER
INITIAL

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent pages, Etc.)

DA	Fagin, "Perspective: Lessons Learned from Molecular Genetic Studies of Thyroid Cancer--Insights into Pathogenesis and Tumor-specific Therapeutic Targets", <i>Endocrinology</i> , Vol. 143, No. 6, pp. 2025-2028 (2002).
DB	Frasca et al., "Tyrosine Kinase Inhibitor STI571 Enhances Thyroid Cancer Cell Motile Response to Hepatocyte Growth Factor", <i>Oncogene</i> , Vol. 20, No. 29, pp. 3845-3856 (2001).
DC	* Joensuu and Dimitrijevic, "Tyrosine Kinase Inhibitor Imatinib (STI571) as an Anticancer Agent for Solid Tumours", <i>Ann Med</i> , Vol. 33, No. 7, pp. 451-455 (2001).
DD	Loré, Talidis, Di Cairano and Renieri, "Multiple Endocrine Neoplasia Type 2 Syndromes May be Associated with Renal Malformations", <i>J Intern Med</i> , Vol. 250, No. 1, pp. 37-42 (2001).
DE	Meric et al., "Expression Profile of Tyrosine Kinases in Breast Cancer", <i>Clin Cancer Res</i> , Vol. 8, No. 2, pp. 361-367 (2002).
DF	* Podtcheko et al., "The Selective Tyrosine Kinase Inhibitor, STI571, Inhibits Growth of Anaplastic Thyroid Cancer Cells", <i>J Clin Endocrinol Metab</i> , Vol. 88, No. 4, pp. 1889-1896 (2003).
DG	
DH	
DI	
DJ	
DK	
DL	
DM	
DN	

EXAMINER /Leslie A. Royds/ (02/18/2009)

DATE CONSIDERED

*EXAMINER: Initial of reference considered, whether or not citation is in conformance with MPEP 609: Draw a line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /LAR/ (02/18/2009)